Bifogade filer
PDF
Kurs
+2,12%
Kalender
| Tid* | ||
| 2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-28 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2024-05-29 | - | Årsstämma |
| 2024-05-23 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-29 | - | Kvartalsrapport 2023-Q3 |
| 2023-11-16 | - | Extra Bolagsstämma 2023 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2023-05-30 | - | Årsstämma |
| 2023-05-24 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-24 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-26 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-01 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2022-05-31 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-09 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2021-06-08 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-27 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-12 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2020-06-11 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-21 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-02 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2017-06-01 | - | Årsstämma |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-17 | - | Bokslutskommuniké 2016 |
| 2016-11-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-30 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-10 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2016-06-09 | - | Årsstämma |
| 2016-05-20 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-06 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-10 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2015-06-09 | - | Årsstämma |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-11-26 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-22 | - | Kvartalsrapport 2014-Q2 |
| 2014-06-06 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2014-06-05 | - | Årsstämma |
| 2014-05-06 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-11-22 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-23 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-31 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2013-05-30 | - | Årsstämma |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-07 | - | Bokslutskommuniké 2012 |
| 2012-11-01 | - | Kvartalsrapport 2012-Q3 |
| 2012-09-28 | - | Kapitalmarknadsdag 2012 |
| 2012-08-22 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-15 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2012-06-14 | - | Årsstämma |
| 2012-05-10 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-08 | - | Bokslutskommuniké 2011 |
| 2011-11-01 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-23 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-15 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2011-06-14 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-01-26 | - | Bokslutskommuniké 2010 |
| 2010-10-29 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-20 | - | Kvartalsrapport 2010-Q2 |
| 2010-06-09 | - | X-dag ordinarie utdelning GTAB B 0.00 SEK |
| 2010-06-08 | - | Årsstämma |
| 2010-04-30 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-05 | - | Bokslutskommuniké 2009 |
| 2009-10-30 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | NGM |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Today Glycorex Transplantation AB (publ) publish the Annual Report for 2022. A pdf-version of the annual report in Swedish is enclosed to this press release. An English version will be available shortly on https://glycorex.com/investors/financial-reports/.
For more information, please contact:
Johan Lavén, CEO
Email: johan.laven@glycorex.com
Tel: + 46 (0)73 330 92 16
This information is the kind of information Glycorex Transplantation AB (publ) is obliged to make public under the EU Market Abuse Act and the Act on the Securities Market. The information was submitted for publication on April 28, 2023, at 18:00 CET.
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique technology to select and remove specific antibodies in the blood.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplants. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,000 transplants in over 25 countries. In addition to Europe, Glycosorb® ABO is used in Australia, Canada, India, Israel, Mexico, Singapore, South Africa, and Thailand, for example.
The company has also developed a CE-marked medical device product for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B